Latest News

Sign up for our RSS Feed.
27 Apr 2015 NeurOp Announces Strategic Collaboration with Johnson & Johnson Innovation to St ... Read More
2 Oct 2014 NeurOp Receives Milestone Payment as Bristol-Myers Squibb Nominates NMDA Recepto ... Read More
Pipeline

Our most advanced compounds for major depression, neuropathic pain and ischemia demonstrate efficacy in animal models with no apparent toxicity at therapeutic doses. The chart below shows the progress towards our goal of placing a drug candidate in human clinical trials.

NR@B Program Click for more on Major Depression Click for more on Neruonal Protection Click for more on Neuropathic Pain